Zenas BioPharma | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Zenas BioPharma is a biopharmaceutical company founded in 2021, with headquarters in Hong Kong and Boston. The company is dedicated to developing and commercializing innovative immune-based therapies for autoimmune and rare diseases. Zenas aims to become a global leader in this field, focusing on transformative therapies that address significant unmet medical needs.

The organization is advancing two late-stage franchises: Obexelimab, an investigational monoclonal antibody targeting B cell activity in autoimmune diseases, and Orelabrutinib, a selective oral small molecule BTK inhibitor for progressive multiple sclerosis and other indications. It also maintains a robust pipeline of earlier-stage programs, including several candidates with first-in-class potential for various autoimmune conditions. Zenas emphasizes operational excellence and innovation in its drug development process, spanning IND-enabling studies to global clinical trials and commercialization. The company collaborates with partners to expand its pipeline and enhance its impact on patients and the healthcare ecosystem.